Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Drug Discovery Automation - Chemistry Automation & Compound Management

's Biography

, ,

Dr. Mel Reichman received his Ph.D. in Neuroscience from the University of Rochester Center for Brain Research. He has held several leadership positions in pharma over his 20-year career in industry. These include: Head, Cellular Pharmacology Laboratory at G.D. Searle; Head, Molecular Pharmacology Laboratory at Berlex Biosciences; Director New Leads Discovery at Ligand Pharmaceuticals; Head, Head of Drug Discovery Operations at Oncogene Science and Director, HTS Project Planning and Management at DuPont Pharma. He has co-authored 28 peer-reviewed publications and has given over 50 invited talks worldwide on all aspects of drug discovery from concept to clinic. He has been an ad-hoc reviewer for many NIH study sections, is an editor of several leading journals and is a scientific advisor in pharmaceutical R&D for startup companies. He joined Lankenau Institute for Medical Research (LIMR) in 2006 as Senior Investigator and founded the LIMR Chemical Genomics Center (LCGC) in 2007, where he serves as President and CSO.


Double Blinded Drug Discovery (DBD2)™: A New Protected Open Innovation Model

Wednesday, 30 May 2012 at 14:15

Add to Calendar ▼2012-05-30 14:15:002012-05-30 15:15:00Europe/LondonDouble Blinded Drug Discovery (DBD2)™: A New Protected Open Innovation Model

The Lankenau Chemical Genomics Center (LCGC) is a totally new, automated molecular diversity depot (patents issued and pending) offering university networks access to ‘diversity-clustered smart-snapshots (DCSS)’ from big Pharmas’ vast chemical collections, under a symbiotically transformative, public-private consortium for drug discovery research.

Add to Calendar ▼2012-05-30 00:00:002012-05-31 00:00:00Europe/LondonDrug Discovery Automation - Chemistry Automation and Compound